As part of the agreement, Celgene, which will commit $45M to Quanticel during alliance term, will acquire an equity stake in Quanticel and will retain an option to purchase the company.
Quanticel will use its solution to perform single-cell genomic analysis of patient tumor samples and to identify predictive biomarkers for Celgene investigational drugs.
Quanticel will also use its solution to conduct independent drug discovery to produce its own drug candidates under the agreement.
Celgene Global Research and Early Development president Thomas Daniel said Quanticel’s platform approach provides a unique advantage for defining mechanisms of sensitivity and resistance, and for validating and pursuing novel targets for difficult-to-treat cancers.
"We view this scientific collaboration and this business model as an innovative approach with high potential to advance the delivery of impactful cancer drugs to patients in need," Daniel added.
Â